Ozempic (semaglutide) is a GLP-1 receptor agonist licensed for type 2 diabetes management, whilst phenterminea sympathomimetic appetite suppressantis not authorised by the MHRA for use in the UK
Brown JC, Dryburgh JR
doi: 10.3389/fphar.2024.1422740 Received 24 April 2024 Accepted 21 May 2024 Published 14 June 2024 Volume 15 - 2024 Edited by Anca Hermenean, Vasile Goldis Western University of Arad, Romania Reviewed by Danila Gurgone, University of Glasgow, United Kingdom Era Gorica, University of Zurich, Switzerland Updates Copyright 2024 Riemma, Mele, Donniacuo, Telesca, Bellocchio, Castaldo, Rossi, De Angelis, Cappetta, Urbanek and Berrino
The participants were randomly assigned to take either tirzepatide or semaglutide